Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2020 | Reduced postoperative therapy in patients with OPC: ECOG-ACRIN 3311

Barbara Burtness • 28 May 2020
ASCO 2020
Head and Neck Cancer
ECOG-ACRIN 3311

Barbara Burtness, MD, Yale Cancer Center, New Haven, CT, USA, highlights data from the ECOG-ACRIN E3311 study (NCT01898494) which examined the use of reduced postoperative therapy in patients with intermediate risk p16+ oropharynx cancer (OPC). This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

More from Barbara Burtness

0:47
Novel KRAS-targeting agents on the horizon
Barbara Burtness • 7 Aug 2022
0:35
Data on KRAS inhibitors in lung cancer at WCLC 2022
Barbara Burtness • 7 Aug 2022
10:08
Evolving role of HER2 targeted therapies in gastroesophageal cancers
Barbara Burtness • 28 May 2020
4:11
CDKN2A and TP53 mutation in HPV-negative HNSCC
Barbara Burtness • 28 May 2020

Related Videos

1:03
Challenges in implementing liquid biopsies for head and neck cancer
Mouadh Barbirou • 7 Apr 2024
2:43
Molecular profiling of tumor biomarkers in head and neck cancer
Mouadh Barbirou • 7 Apr 2024
1:40
The future of squamous cell carcinoma research at ESMO Asia 2023
Brian Henick • 6 Dec 2023
0:54
The role of immunotherapy in PD-L1 low advanced squamous cell carcinoma
Brian Henick • 6 Dec 2023
The content of VJOncology is intended for healthcare professionals